http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-202190751-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2019-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-202190751-A1 |
| titleOfInvention | METHODS FOR TREATMENT OF MYELOPROLIFERATIVE DISORDERS |
| abstract | The present invention provides methods for treating a myeloproliferative disorder. In some aspects, the present invention provides methods of treating, stabilizing, or reducing the severity or progression of one or more myeloproliferative disorders, comprising administering to a patient previously treated with ruxolitinib a pharmaceutically acceptable composition comprising a compound of Formula I, also known as fedratinib, or a pharmaceutically acceptable salt or hydrate. |
| priorityDate | 2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 19.